Short Interest in Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) Grows By 26.7%

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 615,400 shares, a growth of 26.7% from the December 15th total of 485,600 shares. Based on an average trading volume of 100 shares, the short-interest ratio is presently 6,154.0 days.

Wall Street Analyst Weigh In

Several brokerages have recently commented on RCDTF. Barclays upgraded shares of Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a research report on Tuesday, October 22nd. Royal Bank of Canada upgraded shares of Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Price Performance

Shares of RCDTF stock remained flat at $55.54 during trading hours on Friday. The company has a market cap of $11.46 billion, a PE ratio of 27.77 and a beta of 0.30. The firm has a 50-day moving average of $53.19 and a two-hundred day moving average of $52.47. Recordati Industria Chimica e Farmaceutica has a fifty-two week low of $52.25 and a fifty-two week high of $52.25.

About Recordati Industria Chimica e Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.